申请人:ChemoCentryx, Inc.
公开号:US20140171420A1
公开(公告)日:2014-06-19
Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are diazole lactam derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.
本发明提供了一种作为CCR1受体的有效拮抗剂的化合物,并具有体内的抗炎活性。这些化合物是二唑烷内酰胺衍生物,在制药组合物、治疗CCR1介导疾病的方法以及作为竞争性CCR1拮抗剂鉴定的控制中有用。